Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocuphire Pharma Inc OCUP

Healthcare
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1a... see more

Recent & Breaking News (NDAQ:OCUP)

Ocuphire Expands Prestigious Medical Advisory Board with Six New KOLs to Support Advancement of Late-Stage Ophthalmic Assets Nyxol® and APX3330

GlobeNewswire December 8, 2021

Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)

GlobeNewswire November 23, 2021

Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update

GlobeNewswire November 12, 2021

Ocuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting

GlobeNewswire November 1, 2021

Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases

GlobeNewswire October 7, 2021

Ocuphire's Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meeting

GlobeNewswire October 1, 2021

Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall

GlobeNewswire September 27, 2021

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 3, 2021

Ocuphire Pharma Presenting at Four Conferences in September

GlobeNewswire September 2, 2021

Rexahn Announces Move to Nasdaq

GlobeNewswire May 28, 2019

Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results

GlobeNewswire May 13, 2019

Mid-Day Market Update: Accuray Jumps Following Strong Q2 Results; Rexahn Pharmaceuticals Shares Slide

Benzinga.com  January 23, 2019

Mid-Morning Market Update: Markets Open Higher; Procter & Gamble Tops Q2 Estimates

Benzinga.com  January 23, 2019

Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium

GlobeNewswire January 22, 2019

The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

Benzinga.com  January 18, 2019

Rexahn Announces Presentation of RX-3117 Data at the 2019 ASCO Gastrointestinal Cancers Symposium

GlobeNewswire January 14, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Benzinga.com  January 13, 2019

Market Trends Toward New Normal in CME Group, Ambac Financial Group, Erie Indemnity, FuelCell Energy, Hovnanian Enterprises, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings

GlobeNewswire December 11, 2018

Rexahn Pharmaceuticals Streamlines Operations and Provides Update on Pipeline

GlobeNewswire December 6, 2018

Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors

GlobeNewswire December 3, 2018